Best Practice

  • 1. Name of Journal
    The official journal name is Journal of Acupuncture Research. Abbreviated title is J Acupunct Res.
  • 2. Website

    The URL address of official journal web site is http://e-jar.org

    Aims & Scope statement: https://www.e-jar.org/content/about/aims_and_scope.html

    The Journal of Acupuncture Research (JAR), founded in 1983, is the official international journal of the Korean Acupuncture & Moxibustion Medicine Society. The journal, by providing a platform for dissemination and discussion, aims to strengthen the scientific understanding of the safety and effectiveness (efficacy) of acupuncture and related therapies in integrative medicine as well as in traditional medicine.

    There is a long history of research on acupuncture. Work that takes into account historical empirical evidence, incorporating a broad evidence-based approach to acupuncture, and that is of interest and relevance to those involved in the practice, research, and education of acupuncture-based therapies in health care would be welcome.

    JAR considers to publish editorials, original articles, review articles, short communications, case reports, and letters to the editor on:
    • Acupuncture, including electroacupuncture, laser acupuncture, acupotomy, embedding therapy, acupuncture needling, the development of new acupuncture techniques, exploration of new acupoints
    • Moxibustion
    • Cupping
    • Pharmacopuncture (herbal acupuncture, acupoint injection, aqua-acupuncture)
    • The meridian system and other meridian-related studies (diagnosis—including pattern identification research; acupressure; chuna/tuina; herbal medicine)

    Readership:

    JAR is primarily for Korean Medicine doctors and integrative medicine researchers from around the world. Its readership can be expanded to other positions:
    • Researchers interested in acupuncture and related therapies in integrative medicine as well as in traditional medicine, and Asia-specific chronic musculoskeletal condition (pain) issues
    • Students can seek to understand the recent trends in acupuncture and related therapies in integrative medicine as well as in traditional medicine.
    • Professors on acupuncture medicine can access and adopt a variety of data for education;
    • Policy makers are able to reflect the results of the articles to the national health insurance policies
    Korean Medicine doctors or people involved in the practice, research, and education of acupuncture-based therapies in health care throughout the world can submit a manuscript if the scope is appropriate for JAR. Manuscripts should be submitted in English.
  • 3. Publishing schedule

    https://www.e-jar.org/content/about/about_the_journal.html

    Journal of Acupuncture Research is published quarterly on the last day of February, May, August, and November.
  • 4. Archiving
    Journal of Acupuncture Research is accessible without barrier from Korea Citation Index (https://www.kci.go.kr/) and is archived in the National Library of Korea (https://nl.go.kr) in the event the journal is no longer published.
  • 5. Copyright
    The copyrights of published manuscripts and online (https://www.e-jar.org/) become the permanent property of Korean Acupuncture & Moxibustion Medicine Society, and must not be published elsewhere without written permission. All articles published in the Journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article, as well as translation rights. However, the legal responsibility for the content lies entirely with the authors. No part of this publication may be reproduced, stored in any retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording, or otherwise, without prior written permission from Korean Acupuncture & Moxibustion Medicine Society. All authors are to thoroughly read and sign “Authorship Responsibility and Copyright Transfer (Journal Publishing Agreement)” form of Korean Acupuncture & Moxibustion Medicine Society and submit it with the manuscript through the online submission system (https://submit.e-jar.org/).
  • 6. Licensing

    This is an Open Access journal distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

    The content from JAR in part or in whole may be used, reproduced, disseminated, or displayed for non-commercial purposes. Customary bibliographic citations, including author and publisher attribution, date, article title, JAR must be indicated as reference. If an original work is subsequently reproduced or disseminated not in its entirety (i.e., only in part or as a derivative work), this must be clearly indicated. Archiving the manuscript or the publicated article of JAR on another archiving organization is not available without permission of the editorial office of JAR (jared@e-jar.org).

    The permission MUST be obtained from the editorial office of JAR (jared@e-jar.org) prior to any commercial use of material from the open access version of the journal:

    • Reuse of an article or articles in part or in whole in another publication (journal or book) to be sold for commercial purposes.
    • The proactive supply of multiple print or electronic copies of items taken from the journal to third parties on a systematic basis for marketing purposes.
    • Reuse by an author of an article in part or in whole in other publications for commercial organizations.
  • 7. Publication ethics and related editorial policies

    https://www.e-jar.org/content/policy/publishing_ethics_guideline.html

    JAR adheres to the guidelines and best practices published by professional organizations, including ICMJE Recommendations and the Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by the Committee on Publication Ethics, COPE; the Directory of Open Access Journals, DOAJ; the World Association of Medical Editors, WAME; and Open Access Scholarly Publishers Association, OASPA; https://doaj.org/bestpractice). Furthermore, all processes of handling research and publication misconduct shall follow the applicable COPE flowchart (https://publicationethics.org/resources/flowcharts).

    Authorship

    All authors must meet the authorship criteria of ‘Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals’ listed on https://www.icmje.org/. Qualifying for authorship is required for all authors and the order of authorship is to be decided between the coauthors. The authorship credit should be based on substantial contributions to: (1) substantial contributions to the conception or designing of the work; or the acquisition, analysis, or interpretation of data for the work; (2) drafting or revising of the work critically for important intellectual content; (3) final approval of the version to be published; and (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Any persons who do not meet the 4 criteria above should be placed as contributors in Acknowledgments section.

    One author should be chosen to act as a corresponding author. The corresponding author does not have to be the first author. The corresponding author will be responsible for the entire communications to/from the Editorial Office, editors and etc. In case of multicenter studies, a corporate author directly responsible for the manuscript should be appointed.

    Correction of authorship: Any requests for such changes in authorship (adding author(s), removing author(s), or rearranging the order of authors) after the initial manuscript submission and before publication should be explained in writing to the editor in a letter or email from all authors. This letter must be signed by all authors of the paper. A copyright assignment must be completed by every author.

    Managing cases of research and publication misconduct

    When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, falsification of data, plagiarism, improprieties of authorship, undisclosed conflicts of interest, misappropriation of the ideas of others, violation of generally accepted research practices, material failure to comply with legislative and regulatory requirements affection research, inappropriate behavior in relation to misconduct, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (https://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

    Redundant publication and plagiarism

    Attempting to publish substantially similar work more than once without attribution of the original source(s) is considered a redundant publication. Definition of being substantially similar can be explained as follows:
    • At least one of the authors is common to all reports (it is likely to be plagiarism if there are no common authors);
    • The subject or study populations are same or similar;
    • The methodology is typically identical or nearly so and;
    • The results and interpretation varies little or not at all.
    If all or part of the subject population has been reported previously, it should be declared in the Materials and Methods and must be appropriately referenced. In cases where authors are concerned with any potential overlap with published manuscripts or manuscripts being reviewed, the authors must include a letter explaining how the manuscript submitted to JAR significantly differs from other materials. For more information, please refer to ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’ (Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142758/).

    Secondary publication

    It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the ICMJE Recommendations (http://www.icmje.org/urm_main.html).

    Conflict of interest statement

    The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.

    Human and animal rights

    Animal experiments should also be reviewed by an appropriate committee (IACUC: Institutional Animal Care and use Committee) for the care and the use of animals. Studies involving pathogens requiring a high degree of biosafety should pass review of a relevant committee (IBC: Institutional Biosafety Committee). The editor of JAR may request submission of copies of informed consents from human subjects in all studies or IRB approval documents.
    Articles where human subjects can be identified in descriptions, photographs or pedigrees must be accompanied by a signed statement of informed consent to publish (in print and online) the descriptions, photographs and pedigrees from each subject who can be identified. Articles covering the use of human samples in research and human experiments must be approved by the relevant review committee. Articles covering the use of animals in experiments must be approved by the relevant authorities.

    Data Sharing Policy: https://www.e-jar.org/content/policy/publishing_ethics_guideline.html

    JAR follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. More detailed information can be found at the journal’s homepage (https://www.e-jar.org/content/policy/data_sharing_policy.html).

    Journal policies on data sharing and reproducibility; https://www.e-jar.org/content/policy/data_sharing_policy.html
    JAR follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial’s registration. The ICMJE’s policy regarding trial registration is explained at https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.

    Table 1. Examples of data sharing statements that fulfill these ICMJE requirements*
    ICMJE 관련 안내 테이블
    Element Example 1 Example 2 Example 3 Example 4
    Will individual participant data be available (including data dictionaries)? Yes Yes Yes Yes
    What data in particular will be shared? All individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
    What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
    When will data be available (start and end dates)? Immediately following publication. No end date. Beginning at 3 months and ending at 5 years following the article publication. Beginning at 9 months and ending at 36 months following the article publication. Not applicable
    With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. Not applicable
    For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not applicable
    By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Not applicable
    Data are available for 5 years at a third-party website (link to be included). Information regarding submitting proposals and accessing data may be found at (link to be provided).
    ICMJE = International Committee of Medical Journal Editors.
    *These examples are meant to illustrate a range of, but not all, data sharing options.
  • 8. Peer Review

    https://www.e-jar.org/content/authors/instruction_for_authors.html

    Double blind peer review

    JAR operates a double blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final. All submitted manuscripts are screened for duplication through Crosscheck (https://app.ithenticate.com) before review.

    Peer review Process

    The Editorial Office of Journal of Acupuncture Research receives and reviews all submitted manuscripts, and all submitted manuscripts are considered confidential. The submitted manuscripts are initially screened for the format. Once the manuscript is provisionally accepted, it is sent to the three most relevant referees for review. The referees are selected by the editor from the Editorial Board's database or the board members' recommendation. The referees are then requested to evaluate based on originality, validity, presentation, and importance and interest, and, when considered necessary, statistics.

    Acceptance of a manuscript depends on the evaluation, critiques, and recommended decision made by the referees. A referee may recommend 'accept', 'minor revision', 'major revision' and 'reject'. Upon opposing recommended decisions between referees, or author and referee(s), the Editor-in-Chief has the full right to decide whether the manuscript will be published in the journal. Three repeated decisions of 'major revisions' are regarded as a 'reject' and rejected papers will not be considered further.

    The reviewed manuscripts with comments, recommended directions, and revisions are returned to the corresponding author. The corresponding author is to submit the revised manuscript accompanied by point-to-point replies to the comments given by the editor and how the revisions have been made. There should be a reasonable explanation for any noncompliance with the recommendations. In cases where references, tables, or figures are moved, added or deleted during the revision process, renumbering must be done so that all references, tables, and figures are cited in numeric order. If the revised paper is not received within 2 months of decision, the manuscript is considered to have been withdrawn.

    When the final decision on the acceptance of the manuscript is made, the Editorial Office notifies the corresponding author. The peer-review process takes approximately 8-12 weeks.

    Appeals of decisions

    Any appeal against an editorial decision must be made within 2 weeks of the date of the decision letter. Authors who wish to appeal against a decision should contact the editor-in-chief, explaining in detail the reasons for the appeal. All appeals will be discussed with at least one other associate editor. If consensus cannot be reached thereby, an appeal will be discussed at a full editorial meeting. The process of handling complaints and appeals follows the guidelines of COPE available from (https://publicationethics.org/appeals). Journal of Acupuncture Research does not consider second appeals.

  • 9. Access

    https://www.e-jar.org/content/about/open_access.html

    Journal of Acupuncture Research is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derives License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Author(s) do not need to be permitted for use of tables or figures published in JAR in other journals, books, or media for scholarly and educational purposes. This is in accordance with the Budapest Open Access Initiative definition of open access.
  • 10. Ownership and management

    The journal is owned by the Korean Acupuncture & Moxibustion Medicine Society(http://www.kamms.org)
    The management team is as follows:

    Editor-in-Chief

    Ho-Sueb Song Gil Korean Medical Hospital, Gachon University, Korea

    Editors for the Review

    Gi Young Yang Pusan National University School of Korean Medicine, Korea
    Eun jung Kim College of Oriental Medicine, Dongguk University, Korea
    Byung-Kwan Seo Kyung Hee University Hospital at Gangdong, Korea
    Myeong Soo Lee Korea Institute of Oriental Medicine, Korea
    Sang-Hoon Lee Kyung Hee University Korean Medicine Hospital, Korea

    Assistant Editor

    Aejin Song College of Korean Medicine, Gachon University, Korea

    Statistical Editor

    Seung-Deok Lee Dongguk University Los Angeles, USA

    Managing Editor

    Jihye Hwang Gil Korean Medical Hospital, Gachon University, Korea

    Manuscript Editor

    Sujin LeeMEDrang Inc., Korea

    Layout Editor

    Beom Mun MEDrang Inc., Korea

    Website and JATS XML Producer

    Goun Bae INFOrang Inc., Korea

  • 11. Advisory body
    The advisory body is the editorial board of Acupuncture of Research.
  • 12. Editorial team and contact information

    https://www.e-jar.org/content/about/editorial_board.html

    The Editorial team is available from Editorial Board page at the front part of the journal.

    Editor-in-Chief : Ho-Sueb Song Gil Korean Medical Hospital, Gachon University, Korea
    E-mail : docsong70@hanmail.net

    Editorial Office

    Aejin Song
    Korean Acupuncture & Moxibustion Medicine Society
    Gil Korean Medical Hospital, Gachon University
    Keunumul-Ro, Chung-Ku, Inchoen 22138, Korea
    Tel: +82-70-7606-6353,4
    Fax: +82-32-232-3334
    E-mail: jared@e-jar.org
  • 13. Author fees
    The author does not have any article processing charge for publication. There is also no publishing fee and Korean Acupuncture & Moxibustion Medicine Society will pay to make the article for open access.
  • 14. Other revenue
    This journal was supported by Korean Acupuncture & Moxibustion Medicine Society and the Korean Federation of Science and Technology Societies Grant funded by Korean Government (Ministry of Education). The Editorial Board ensures that business models or revenue streams do not influence the decision to accept manuscripts.
  • 15. Advertising
    The advertisement price for one whole page is USD 1,000. Depends on number of pages and banner advertisements on the website, the price is negotiable.
  • 16. Direct marketing
    Journal propagation has been done through the journal website and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on presenters at conferences, seminars, or workshops if the topic is related to the journal’s aims and scope.
JAR
Feb 28, 2023 Vol.40 No.1, pp. 1~96

Most KeyWord ?

What is Most Keyword?

  • It is most registrated keyword in articles at this journal during for 2 years.

Most View

Most Cited

Editorial Office

Journal of Acupuncture Research

pISSN 2586-288X
eISSN 2586-2898
qr-code Download